Table 13.

Risks associated with discouraging participation in HIV cure research (HIV+ vs HIV− participants)

	HIV+ N=47			HIV– N=71			PR
	Answered N	Yes %	Missing data N (%)	Answered N	Yes %	Missing data N (%)	P value
Musculoskeletal side effects	33	76	14 (30)	36	64	35 (49)	0.28
Dermatological side effects	37	73	10 (21)	41	60	30 (42)	0.18
Psychological side effects	30	73	17 (36)	40	60	31 (44)	0.24
Toxicities/adverse side effects	29	72	18 (38)	38	68	33 (47)	0.72
Potential for drug resistance development	28	71	19 (40)	38	56	33 (47)	0.26
HIV-related side effects	34	71	13 (28)	40	58	31 (44)	0.24
Pain or discomfort	31	71	16 (34)	34	56	37 (52)	0.21
Gastrointestinal side effects	33	70	14 (30)	35	57	36 (50)	0.28
Neurological side effects	26	69	21 (44)	37	62	34 (48)	0.56
Unknown side effects	29	69	18 (38)	33	52	38 (54)	0.16
Potential for virus rebound if ART is stopped	29	66	18 (38)	41	51	30 (42)	0.23
Taking time away from family	27	59	20 (42)	28	57	43 (61)	0.87
Long-term follow-up for safety and outcomes	31	58	16 (34)	41	54	30 (42)	0.71
Long study visits (4+ hours)	30	57	17 (36)	31	52	40 (56)	0.69
Activation of cancer-causing genes	28	54	19 (40)	35	49	36 (51)	0.69
GVHD	28	54	19 (40)	40	55	31 (44)	0.90
Taking time away from work	27	52	20 (42)	32	53	39 (55)	0.92
Invasive study procedures	27	48	20 (42)	37	60	34 (48)	0.37
Having to stay in hospital overnight	29	48	18 (38)	32	50	39 (55)	0.89
Allergic reactions	28	23	19 (40)	32	60	39 (55)	0.05

GVHD, graft versus host disease; PR, prevalence ratio.